Jazz Pharmaceuticals (JAZZ) Reports In-Line Q2 EPS, Reaffirms FY Guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $2.41, in-line with the analyst estimate of $2.41. Revenue for the quarter came in at $333.7 million versus the consensus estimate of $335.86 million.

Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.75, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015 revenue of $1.31-1.37 billion, versus the consensus of $1.36 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Goldman Sachs Assumes Jazz Pharmaceuticals (JAZZ) at Buy
• Darden Restaurants (DRI) Reports In-Line Q1 EPS, Misses on Revenue; Offers FY27 EPS Guidance
• Moody’s upgrades Brinker to Ba1 on Chili’s growth and debt reduction